| Madelynn Jae Barnhill, PA | |
|
340 Ezra Emison Rd, Bells, TN 38006-4243 | |
| (731) 571-8555 | |
| Not Available |
| Full Name | Madelynn Jae Barnhill |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Location | 340 Ezra Emison Rd, Bells, Tennessee |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801649124 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Madelynn Jae Barnhill, PA 340 Ezra Emison Rd, Bells, TN 38006-4243 Ph: (731) 571-8555 | Madelynn Jae Barnhill, PA 340 Ezra Emison Rd, Bells, TN 38006-4243 Ph: (731) 571-8555 |
News Archive
A plane has to be going pretty fast for a mere raindrop to crack its windshield, but it can happen. Now, new models of the physics behind the improbable feat may just help doctors crack kidney stones to pieces.
Current screening strategies for Down syndrome, caused by fetal trisomy 21 (T21), and Edwards syndrome, caused by fetal trisomy 18 (T18), have false positive rates of 2 to 3%, and false negative rates of 5% or higher. Positive screening results must be confirmed by amniocentesis or chorionic villus sampling, which carry a fetal loss rate of approximately 1 in 300 procedures. Now an international, multicenter cohort study finds that a genetic test to screen for trisomy 21 or 18 from a maternal blood sample is almost 100% accurate.
Scientists from the Florida campus of The Scripps Research Institute have identified for the first time a novel mechanism that regulates circadian rhythm, the master clock that controls the body's natural 24-hour physiological cycle. These new findings could provide a new target not only for jet lag, shift work, and sleep disturbances, but also for disorders that result from circadian rhythm disruption, including diabetes and obesity as well as some types of cancer.
Researchers have safely transplanted stem cells derived from a patient's skin to the back of the eye in an effort to restore vision. The research is being presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Seattle, Wash.
Tigris Pharmaceuticals, Inc., has announced that its Investigational New Drug (IND) application for the Company's geranylgeranyltransferase inhibitor (GGTI-2418) has been accepted by the U.S. Food and Drug Administration.
› Verified 3 days ago